B2B Takes a Backseat for Public-to-Private Buyouts
September 13, 2012
Thoma Bravo has entered into an agreement to take Mediware Information Systems (NASDAQ: MEDW) private for $22 per share, which puts the total transaction value at $195 million. The per share price represents a 40% premium. Mediware provides clinical software solutions, including blood management, cell therapy, medication management and business intelligence-based performance management solutions.
PE-backed take-private buyout activity has calmed down since its heyday in 2007, but PE investors have still been seizing several acquisition opportunities in the public markets. Since the beginning of 2008, they have taken 180 public U.S. companies private, including 21 from this year, according to the PitchBook Platform. An additional 12 such transactions have been announced in 2012 but have yet to be completed. Unlike PE investment activity as a whole, public-to-private buyout activity is not led by the B2B industry. Instead, B2C and Information Technology have led the take-private deal flow since 2008, each accounting for a 24% share.
PitchBook Platform users can click on the chart above or here to customize it.